Drug intelligence / Profile preview

MNE-P201

Development stage: Preclinical
Lead developer: myNEO Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

MNE-P201 is a personalized mRNA-based cancer vaccine being developed by myNEO Therapeutics for the treatment of solid tumors. The vaccine is designed using the company's proprietary neoantigen identification platform to encode patient-specific mutations (neoantigens) that are unique to the individual's tumor. Upon administration, the mRNA is translated into neoantigenic proteins, which are then presented to the immune system to trigger a targeted T-cell response against the cancer cells. MNE-P201 is currently in preclinical development.

Targets

Neoantigen-specific T-cell receptorPatient-specific tumor neoantigen peptides presented on Human Leukocyte Antigen (HLA) molecules

Beyond the preview

Go deeper on MNE-P201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNE-P201.

Explore the full profile